The top 3 holdings of LABU are Alnylam Pharmaceuticals (ALNY) (2.198%), Halozyme Therapeutics (HALO) (1.984%) and Insmed (INSM) (1.937%).

FUND	HOLDING	% OF FUND	VALUE ($)
LABU	Alnylam Pharmaceuticals (ALNY)	2.198%	$14.2M
LABU	Halozyme Therapeutics (HALO)	1.984%	$12.8M
LABU	Insmed (INSM)	1.937%	$12.5M
LABU	Incyte (INCY)	1.821%	$11.7M
LABU	United Therapeutics (UTHR)	1.634%	$10.5M
LABU	Regeneron Pharmaceuticals (REGN)	1.634%	$10.5M
LABU	AbbVie (ABBV)	1.604%	$10.3M
LABU	Neurocrine Biosciences (NBIX)	1.596%	$10.3M
LABU	Madrigal Pharmaceuticals (MDGL)	1.557%	$10M
LABU	Gilead Sciences (GILD)	1.545%	$10M
LABU	Biogen (BIIB)	1.516%	$9.8M
LABU	Biomarin Pharmaceutical (BMRN)	1.514%	$9.8M
LABU	Amgen (AMGN)	1.462%	$9.4M
LABU	Natera (NTRA)	1.441%	$9.3M
LABU	BridgeBio Pharma (BBIO)	1.432%	$9.2M
LABU	Exelixis (EXEL)	1.353%	$8.7M
LABU	Moderna (MRNA)	1.351%	$8.7M
LABU	Vertex Pharmaceuticals (VRTX)	1.271%	$8.2M
LABU	EXACT Sciences (EXAS)	1.214%	$7.8M
LABU	Roivant Sciences (ROIV)	1.058%	$6.8M
LABU	Cytokinetics (CYTK)	0.965%	$6.2M
LABU	Crispr Therapeutics (CRSP)	0.953%	$6.1M
LABU	Ionis Pharmaceuticals (IONS)	0.932%	$6M
LABU	Avidity Biosciences (RNA)	0.884%	$5.7M
LABU	Revolution Medicines (RVMD)	0.84%	$5.4M

Holdings are tracked for approximately 2000 ETFs.